Norris Perne & French LLP MI Sells 3,948 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Norris Perne & French LLP MI reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 126,054 shares of the medical research company's stock after selling 3,948 shares during the quarter. Charles River Laboratories International makes up approximately 1.7% of Norris Perne & French LLP MI's portfolio, making the stock its 23rd largest position. Norris Perne & French LLP MI owned about 0.25% of Charles River Laboratories International worth $23,270,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Empirical Finance LLC boosted its stake in Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company's stock worth $258,000 after buying an additional 53 shares in the last quarter. American Trust lifted its holdings in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company's stock worth $202,000 after acquiring an additional 54 shares during the period. OLD National Bancorp IN boosted its position in shares of Charles River Laboratories International by 3.1% during the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company's stock valued at $392,000 after acquiring an additional 59 shares in the last quarter. Fiduciary Financial Group LLC increased its stake in Charles River Laboratories International by 3.9% in the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company's stock valued at $310,000 after acquiring an additional 63 shares during the period. Finally, Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock worth $35,000 after purchasing an additional 65 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. StockNews.com downgraded Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Thursday, November 7th. TD Cowen upped their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research report on Monday, November 11th. CLSA cut Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price objective for the company. in a report on Monday, November 18th. The Goldman Sachs Group lowered their target price on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating on the stock in a report on Thursday, January 23rd. Finally, William Blair downgraded shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a report on Wednesday, January 22nd. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $204.38.

Insider Buying and Selling at Charles River Laboratories International

In related news, Director Richard F. Wallman sold 6,621 shares of the business's stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company's stock, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.30% of the company's stock.

Charles River Laboratories International Trading Down 0.4 %

CRL stock traded down $0.69 during trading on Friday, hitting $164.88. The company had a trading volume of 623,019 shares, compared to its average volume of 867,492. The firm has a 50-day moving average price of $184.15 and a 200-day moving average price of $195.45. Charles River Laboratories International, Inc. has a 12 month low of $159.65 and a 12 month high of $275.00. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. The stock has a market cap of $8.43 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 6.13 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.43 by $0.16. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm's quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.72 earnings per share. As a group, analysts predict that Charles River Laboratories International, Inc. will post 10.17 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).